Navigation Links
Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer
Date:10/10/2008

BALTIMORE, Oct. 10 /PRNewswire/ -- A nationally recognized faculty will present the very latest treatment strategies for patients with breast cancer in the multimedia course "Optimizing Adjuvant Breast Cancer Strategies: From Biomarkers to Treatment Selection" during National Breast Cancer Awareness Month.

It is challenging for practicing oncologists and other interested health care providers to stay up to date on the latest patient care advances. This accredited course offers concise, expert reporting on key, practical treatment innovations, including research from recent American Society of Clinical Oncology (ASCO) annual meetings and San Antonio Breast Cancer Symposia.

-- Program Chair Antonio C. Wolff, MD, FACP, of the Johns Hopkins Sidney

Kimmel Comprehensive Cancer Center, will discuss biomarkers.

-- Harold J. Burstein, MD, PhD, from the Breast Oncology Center, the

Dana-Farber Cancer Institute, and Harvard Medical School, will present

on recent developments in chemotherapy-biologic treatments.

-- Ana Maria Gonzalez-Angulo, MD, MSc, of The University of Texas M. D.

Anderson Cancer Center, will discuss the issue anthracycline related

cardiotoxicity

Physicians can register for and take this accredited, virtual e-conference course at any time beginning Tuesday, October 14, 2008 at http://www.virtualbreastcancer.com. Participants learn at their own pace and utilize interactive case studies, choosing treatments for simulated patients, and receiving feedback on their decisions.

As a bonus, the faculty will offer a "Live Question-and-Answer Session" on October 14, 2008, from noon to 2:00pm (EDT). The course, including faculty presentations and questions and answers generated on October 14, will remain available for one year.

The course is presented by The Johns Hopkins University School of Medic
'/>"/>

SOURCE PharmacoMedia LLC
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
2. Blue Cross and Blue Shield Association Nationally Recognized by BusinessWeek and AARP for Creating a Unique Workplace Environment for New and Mature Employees
3. Nationally Recognized Corporations and Retailers Rally Behind breastcancer.org
4. UPMC and UPMC Health Plan Recognized Nationally for Quality Leadership in Employee Health and Productivity
5. Nationally-Recognized Georgia Diabetes Project Honored
6. HealthONE(R) Appoints Nationally Renowned Pediatric Cardiologist & Childhood Obesity Expert as First Chief Medical Officer for the Rocky Mountain Hospital for Children(SM)
7. CytoCare Showcased on CBS News Nationally and CBS Affiliates
8. Health Care Districts Board Chair Nationally Recognized as a Modern Healthcare Trustee of the Year
9. Global Med Technologies(R), Inc. Adds Internationally Renowned NewYork- Presbyterian Hospital to Client List
10. Nationally Recognized Information Technology Veteran and Entrepreneur John Bamberger Joins gloStream, Inc. as Chief Channel Officer
11. Anti-Aging/Genetic Health Leader Suracell, Inc. Expands Internationally
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...0th anniversary of drive to eliminate lymphatic fi...dazole tablet and grant to The Carter Center , ...FirstCall/ -- In a meeting today with former U.S. ...Carter, as well as global health thought leaders f... GSK ) announced that it has made a $250,000 donat...
(Date:12/4/2008)... Aurora Health Care is ramping up ...ements. Aurora,s Care Management,Clinical Leaders...l Aurora,caregivers about the benefits of Vitamin...ce that higher Vitamin D levels may improve outcom... certain muscle conditions and,seasonal depressio...
(Date:12/4/2008)... Dec. 4 BAPTIST HEALTH, a six-hosp...tate,s largest health system, has,expanded its us...ters -- a,solution that enabled the system,s phar...ons and save more than $1 million. , "Data ...pus show that,CareFocus prompts approximately hal...
(Date:12/4/2008)...uilt Unites Leaders of Virginia, Maryland and D.C....swire-USNewswire/ -- Nationally, Washington, D.C. ...AIDS in D.C., 82 percent are African American. In... D.C. and the South, today,s Living Quilt roundtab...ogether the leaders of the Virginia, Maryland and ...
Breaking Medicine News(10 mins):Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 2Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 3Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 4Health News:Aurora Health Care Urges All Wisconsin Residents to Take Vitamin D 2Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 2Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 3Health News:Southern AIDS Living Quilt Raises Awareness in Washington, D.C. 2Health News:Southern AIDS Living Quilt Raises Awareness in Washington, D.C. 3
...archers in the US have developed a way to print DN... day make genetic tests as cheap as blood tests. T...SuNS) uses handy genetic tools called microarrays,...d in medical diagnostics.// The new technique has...
...archers at the University of Texas Medical Branch ...the proteins in the blood that cause the “mad cow ...t is now possible to detect biochemically the prio... the disease.// The study was reported in the cur...
...is all set to start a free screening program to de...prevent loss of legs from diabetes amputations. Ca...he onset of the condition early and can help to re...on by half. // People with diabetes are especial...
...immune system has the remarkable ability to discri...ffective functioning of the immune system, the hum... diseases eventually leading to death. // The imm...alled antibodies, which identify the invading path...
Other Medicine News:Health News:Diabetic Amputation May Reduce If Free Screenings Are There 2Health News:Fighting against disease as easy as eating eggs 2
(Date:12/4/2008).../ -- Velos, Inc., the recognized leader and truste...ion systems, today announced that it has signed an...Center (KU Medical Center). KU Medical Center wil...m-wide roll-out that supports the regulatory, admi...ds of the institution,s clinical research programs...
(Date:12/3/2008)...wire/ -- The Leukemia & Lymphoma Society (LLS)... a new clinical trial of ISF35, a cancer vaccine, ...). , , LLS is collaborating on this trial...nd approval of a novel approach aimed at treating ...leted chronic lymphocytic leukemia (CLL). , ,...
(Date:12/3/2008)...tCall/ -- Vical Incorporated,(Nasdaq: VICL ) to...nt with EIP,Eczacibasi Ilac Pazarlama A.S. (EIP) ...in-7(R) immunotherapeutic product candidate in Tur...EIP has agreed to obtain the necessary regulatory,...ont and milestone payments,plus a specified trans...
(Date:12/2/2008)...re/ -- TorreyPines Therapeutics, Inc. (Nasdaq: T...atient Phase II trial evaluating three doses of NG...in patients with Sjogren,s syndrome. NGX267 met t... increase in salivary flow production compared to ...g. These doses were safe and well tolerated with f...
Breaking Medicine Technology:University of Kansas Medical Center to Deploy Velos eResearch System-Wide 2University of Kansas Medical Center to Deploy Velos eResearch System-Wide 3The Leukemia & Lymphoma Society and Memgen Announce New Chronic Lymphocytic Leukemia Clinical Trial 2The Leukemia & Lymphoma Society and Memgen Announce New Chronic Lymphocytic Leukemia Clinical Trial 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 2Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 5TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 2TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 3TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 4TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 5RSB Spine LLC Announces FDA Clearance of New InterPlate 28TM 29 Indications 1772 1Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 1770 1Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 1770 2Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 1770 3Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 1770 4Small Bone Innovations Introduces the Artelon 28R 29 STT Spacer to Increase Treatment Options for Thumb Arthritis 1768 1Small Bone Innovations Introduces the Artelon 28R 29 STT Spacer to Increase Treatment Options for Thumb Arthritis 1768 2Small Bone Innovations Introduces the Artelon 28R 29 STT Spacer to Increase Treatment Options for Thumb Arthritis 1768 3Small Bone Innovations Introduces the Artelon 28R 29 STT Spacer to Increase Treatment Options for Thumb Arthritis 1768 4Small Bone Innovations Introduces the Artelon 28R 29 STT Spacer to Increase Treatment Options for Thumb Arthritis 1768 5Saflink and IdentiPHI Announce Merger Agreement 521 1Saflink and IdentiPHI Announce Merger Agreement 521 2Saflink and IdentiPHI Announce Merger Agreement 521 3Saflink and IdentiPHI Announce Merger Agreement 521 4Saflink and IdentiPHI Announce Merger Agreement 521 5
...if.--(BUSINESS WIRE)--Jun 8, 2007 - AVANIR,Pharmac...ation of,Phase III data, including efficacy, safet... patients with diabetic peripheral,neuropathic (DP...ia(TM) (dextromethorphan/quinidine (DM/Q)), an NMD...a were accepted as,late-breakers, and presented i...
...--(BUSINESS WIRE)--Jun 8, 2007 - Archemix Corp., a...developing,aptamers, announced the successful comp...rapeutic, ARC1779. ARC1779 is designed to,selectiv... of,platelets by inhibiting the binding of von Wil...lets. Activated vWF is scientifically,recognized a...
Other Medicine Technology:AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 2AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 3AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 4AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 5AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 6AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 7Archemix Announces Completion of Phase 1 Trial of ARC1779 2Archemix Announces Completion of Phase 1 Trial of ARC1779 3
...you can perform stereotactic, ultrasound and MRI-g...nience of your office. Use the patented, FDA-clear...e clinically advanced method of breast biopsy. Its...trust YOU.,9 Gauge Handpieces: Useful for bio...
36" Penrose drains
12" Penrose drains
Offers a more constant suction profile than three-spring evacuators, resulting in the potential for improved tissue approximation and reduced risk of hematoma.
Medicine Products: